EMA Approval Submission for Teclistamab Multipl...

By HEOR Staff Writer

March 12, 2026

Johnson & Johnson has submitted a Type II variation application to the
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
FDA Biosimilar Approval Reforms: Accelerating Access and Reducing Drug Costs
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...
Aspen Pharmacare Financial Growth: Navigating H1 2026’s Transitional Fi...
South Africa’s Push for Local Lenacapavir Production to Enhance HIV Pre...
Urgent Call for Enhanced Precision Oncology Access in Europe
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU